This company listing is no longer active
Metacrine Balance Sheet Health
Financial Health criteria checks 6/6
Metacrine has a total shareholder equity of $37.1M and total debt of $13.8M, which brings its debt-to-equity ratio to 37.2%. Its total assets and total liabilities are $55.0M and $18.0M respectively.
Key information
37.2%
Debt to equity ratio
US$13.79m
Debt
Interest coverage ratio | n/a |
Cash | US$52.75m |
Equity | US$37.07m |
Total liabilities | US$17.97m |
Total assets | US$55.04m |
Recent financial health updates
Recent updates
Equillium acquires Metacrine to extend cash runway through 2024
Sep 06Metacrine initiated buy at H.C. Wainwright citing novelty in therapeutic platform
Jun 14Metacrine completes enrollment in mid-stage NASH trial
Jun 02Metacrine initiates mid-stage study of MET409 + empagliflozin in diabetes and NASH
Jan 05What Percentage Of Metacrine, Inc. (NASDAQ:MTCR) Shares Do Insiders Own?
Dec 16Metacrine reports Q3 results
Nov 12Financial Position Analysis
Short Term Liabilities: MTCR's short term assets ($55.0M) exceed its short term liabilities ($4.5M).
Long Term Liabilities: MTCR's short term assets ($55.0M) exceed its long term liabilities ($13.4M).
Debt to Equity History and Analysis
Debt Level: MTCR has more cash than its total debt.
Reducing Debt: MTCR had negative shareholder equity 5 years ago, but is now positive and has therefore improved.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: MTCR has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: MTCR has sufficient cash runway for 1.4 years if free cash flow continues to reduce at historical rates of 21.8% each year.